



(12) Translation of
European patent specification

(11) NO/EP 3256218 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/4192 (2006.01)
A61P 35/02 (2006.01)
C07C 211/35 (2006.01)
C07C 237/22 (2006.01)
C07D 249/06 (2006.01)

Norwegian Industrial Property Office


(45)	Translation Published	2025.03.31
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.12.11
(86)	European Application Nr.	16749986.2
(86)	European Filing Date	2016.02.12
(87)	The European Application's Publication Date	2017.12.20
(30)	Priority	2015.02.12, US, 201562115474 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Imago Biosciences Inc., 2729 Debbie Court, San Carlos, CA 94070, USA
(72)	Inventor	RIENHOFF, Hugh Young Jr., 2729 Debbie Court, San Carlos, CA 94070, USA MCCALL, John M., 2729 Debbie Court, San Carlos, CA 94070, USA CLARE, Michael, 2729 Debbie Court, San Carlos, CA 94070, USA CELATKA, Cassandra, 2729 Debbie Court, San Carlos, CA 94070, USA TAPPER, Amy E., 2729 Debbie Court, San Carlos, CA 94070, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	A KDM1A INHIBITOR AND ITS USE IN THERAPY
(56)	References Cited:	WO-A1-2015/021128 WO-A1-2017/079753 WO-A1-2014/084298 WO-A1-2014/164867 DANIEL P. MOULD ET AL: "Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to Date : REVERSIBLE INHIBITORS OF LSD1", MEDICINAL RESEARCH REVIEWS, vol. 35, no. 3, 24 November 2014 (2014-11-24), US, pages 586 - 618, XP055441022, ISSN: 0198-6325, DOI: 10.1002/med.21334

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 1.** En forbindelse med formelen:



5

eller et salt, en polymorf, eller et solvat derav.

- 2.** En forbindelse, salt, polymorf, eller solvat som angitt i krav 1, for anvendelse som et medikament.

10

- 3.** En farmasøytisk sammensetning som omfatter en forbindelse, et salt, en polymorf, eller et solvat som angitt i krav 1, sammen med en farmasøytisk akseptabel bærer.

- 4.** En kombinasjon som omfatter en forbindelse, et salt, en polymorf, eller et solvat som angitt i krav 1, og et annet terapeutisk middel.

- 5.** En kombinasjon som angitt i krav 4, for anvendelse i terapi.